drugset / Trial / NCT02330796
Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
RandomizedFactorialOpen-labelTreatment
Summary
A Phase IIA, open-label, multicenter, active-controlled, parallel-group clinical trial designed to evaluate the safety and efficacy of two doses of Bucillamine compared with low-dose Colchicine in the treatment of patients with acute gout flare.
Timeline
- Start
- 2015-04
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bucillamine | Small molecule | 900 mg | — |
| Subject | Bucillamine | Small molecule | 1800 mg | — |
| Comparator | Colchicine | Small molecule | 1.8 mg | — |